World experts target guidance on managing dementia symptoms

August 2, 2018, University of Exeter
Credit: CC0 Public Domain

New research which brings together the views of the world's leading experts has concluded that non-drug approaches should be prioritised in treating agitation in people with Alzheimer's disease.

The research, published in International Psychogeriatrics and led by the University of Michigan, the University of Exeter and John Hopkins University, provided more specific guidance on the management of behavioural and psychological symptoms in people with Alzheimer's disease.

It gives the most specific and targeted treatment for psychosis and agitation. Both symptoms are common in dementia and have a significant impact on individuals, families and carers.

The International Delphi Consensus paper incorporates views of a panel of experts from across the globe, who have both clinical and research expertise. Undertaken as an International Psychogeriatric Association taskforce, it brought together the latest evidence on how best to treat symptoms such as psychosis and agitation, to help get the best treatment for the 40 million people with dementia worldwide.

By ranking available treatments in order of the quality of evidence, the paper provides guidance on the order in which clinicians should prioritize treatments.

For treating agitation in people with dementia, the first four highly ranked treatments were all non-pharmacological approaches. Assessment and management or underlying causes, educating caregivers, adapting environment, person-centred care and a tailored activity programme all ranked more highly than any of the pharmacological treatments. The highest ranked pharmacological treatment was the antidepressant citalopram, which came in at number six.

Of note, of the currently used atypical antipsychotic drugs only risperidone reached consensus as a recommended treatment, at number 7 in the list.

Helen C. Kales, MD, director of the program for positive aging at the University of Michigan and research investigator at the VA Center for Clinical Management Research noted: "This research advocates a significant shift from current practice, recommending that non-pharmacological treatments are a first-line approach for agitation in dementia. Aside from risperidone at number 7 in the list, none of the other were recommended. This is a very welcome change, given the known harms associated with these treatments."

For the treatment of psychosis in people with dementia, including symptoms such as hallucinations and delusions, the panel advocated a thorough assessment and management of underlying causes as the first approach. The atypical antipsychotic came second, as the only pharmacological treatment with any supporting evidence that it works. This highlights a particular gap in the treatment of psychosis in people with dementia, which is a distressing and disabling symptom, and emphasizes tis as a priority area for further research.

Overall, the DICE (describe, investigate, create and evaluate) therapy approach, which involves identifying triggers, and using music were both found to be effective in managing symptoms without prescribing drugs.

Clive Ballard, Professor of Age-Related Diseases at the University of Exeter Medical School, said: "Symptoms such as and agitation can be particularly distressing and challenging for people with , their carers and their families. Many commonly prescribed medications can cause harm, in some cases significantly increasing risk of stroke or death. We now know that non-drug approaches are the best starting points and can prove effective. This research provides more specific and targeted guidance to support clinicians to give the best possible treatment options."

Explore further: Global experts seek to end damaging dementia psychosis cycle

Related Stories

Global experts seek to end damaging dementia psychosis cycle

October 2, 2017
A new research report calls for a change in approach in the treatment of psychosis in dementia, to find alternatives to highly damaging antipsychotics.

Psychosis in Parkinson's dementia—new treatment provides hope

September 25, 2017
New research involving King's College London and the University of Exeter has highlighted the benefits of a promising new treatment which could relieve psychosis in thousands of people with dementia related to Parkinson's ...

Pimavanserin: Relief from psychosis in dementia, without devastating side-effects

February 13, 2018
A new kind of antipsychotic has been found to relieve terrifying and disturbing symptoms suffered by millions of people with Alzheimer's disease worldwide.

Antipsychotics increase risk of death in people with Parkinson's disease psychosis

September 30, 2015
Antipsychotic drugs may increase the risk of death in people with Parkinson's disease psychosis (PDP), according to a new study led by researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's ...

Are antipsychotic drugs more dangerous to dementia patients than we think?

March 18, 2015
Drugs aimed at quelling the behavior problems of dementia patients may also hasten their deaths more than previously realized, a new study finds.

New research focuses on treating non-cognitive symptoms of people with dementia

July 24, 2018
New research presented at the Alzheimer's Association International Conference (AAIC) 2018 in Chicago focuses on the recent successes and ongoing challenges of drug and non-drug treatments for the non-cognitive symptoms experienced ...

Recommended for you

Machine learning uncovers dementia subtypes with implication for drug trials

October 22, 2018
Machine learning could help to find new treatments for dementia, according to researchers at UCL.

Losing control of gene activity in Alzheimer's disease

October 22, 2018
Pioneering research into the mechanisms controlling gene activity in the brain could hold the key to understanding Alzheimer's disease and might help identify effective treatments in the future.

Deep brain stimulation not effective for treating early Alzheimer's

October 22, 2018
A new study from Johns Hopkins shows that individuals with early onset Alzheimer's disease—those under the age of 65—don't benefit from deep brain stimulation, a treatment already proven to be effective for easing motor ...

Hypothesis underpinning dementia research 'flawed'

October 16, 2018
A hypothesis which has been the standard way of explaining how the body develops Alzheimer's Disease for almost 30 years is flawed, according to a University of Manchester biologist.

Study suggests biological basis for depression, anxiety, sleep disturbances in older adults

October 15, 2018
UC San Francisco researchers, in collaboration with the unique Brazilian Biobank for Aging Studies (BBAS) at the University of São Paulo, have shown that the earliest stages of the brain degeneration associated with Alzheimer's ...

Many cases of dementia may arise from non-inherited DNA 'spelling mistakes'

October 15, 2018
Only a small proportion of cases of dementia are thought to be inherited—the cause of the vast majority is unknown. Now, in a study published today in the journal Nature Communications, a team of scientists led by researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.